{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Gordon C S Smith, Alexandros A Moraitis, David Wastlund, Jim G Thornton, Aris Papageorghiou, Julia Sanders, Alexander E P Heazell, Stephen C Robson, Ulla Sovio, Peter Brocklehurst & Edward C F Wilson.

Gordon C S Smith ^1,*, Alexandros A Moraitis ¹, David Wastlund ², Jim G Thornton ³, Aris Papageorghiou ⁴, Julia Sanders ⁵, Alexander E P Heazell ⁶, Stephen C Robson ⁷, Ulla Sovio ¹, Peter Brocklehurst ⁸, Edward C F Wilson ^2,9

¹ Department of Obstetrics and Gynaecology, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
² The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
³ Division of Child Health, Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Nottingham, UK
⁴ Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, UK
⁵ School of Healthcare Sciences, Cardiff University, Cardiff, UK
⁶ Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, UK
⁷ Reproductive and Vascular Biology Group, The Medical School, Newcastle University, Newcastle upon Tyne, UK
⁸ Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
⁹ Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, UK
^* Corresponding author Email: gcss2@cam.ac.uk

Declared competing interests of authors: Gordon CS Smith reports grants from the Medical Research Council, National Institute for Health Research (NIHR) Health Technology Assessment (HTA), the Wellcome Trust and Wellbeing of Women (London, UK); grants and personal fees from GlaxoSmithKline Research and Development Ltd (GlaxoSmithKline plc, Brentford, UK), grants from Sera Prognostics Inc. (Salt Lake City, UT), non-financial support from Illumina Inc. (San Diego, CA), and personal fees from Roche Diagnostics Ltd (Basel, Switzerland) outside the submitted work. Jim G Thornton is a member of the NIHR HTA and Efficacy and Mechanism Evaluation Editorial Board. Aris Papageorghiou reports personal fees from educational events/lectures, clinical services in the private sector and consultancy via Oxford University Innovation, royalties from published works, and editorial work for Ultrasound in Obstetrics and Gynecology and British Journal of Obstetrics and Gynaecology outside the submitted work. Ulla Sovio reports grants from the NIHR Cambridge Biomedical Research Centre during the conduct of the study. Peter Brocklehurst reports grants and personal fees from the Medical Research Council, grants from the NIHR Health Services and Delivery Research programme, the NIHR HTA programme and the Wellcome Trust, and personal fees from AG Biotest (Dreieich, Germany) outside the submitted work. In addition, Gordon CS Smith and Ulla Sovio have a patent in preparation for a novel predictive test for fetal growth restriction pending.